Tiotropium + Olodaterol (Stiolto Respimat)

Indications

  • Chronic Obstructive Pulmonary Disease (COPD) (see Chronic Obstructive Pulmonary Disease, [[Chronic Obstructive Pulmonary Disease]])
  • Note: Tiotropium + Olodaterol is not indicated for the treatment of asthma

Pharmacology

Metabolism

  • xxx

Administration

  • INH

Dose Adjustment

  • Hepatic: xxx
  • Renal: xxx

Adverse Effects

Allergic Adverse Effects

Otolaryngologic Adverse Effects

  • Nasopharyngitis: occurs in 12.4% of cases

Pulmonary Adverse Effects

Other Adverse Effects

  • Back Pain (see Back Pain, [[Back Pain]]): occurs in 3.6% of cases

References

  • xxx